Why are the risks of gene drive technologies being assessed on a case-by-case basis?
Risk assessments will be conducted separately for each gene drive-modified product, taking into consideration the particular conditions under which it will be tested or used. Each individual product will reflect a unique combination of characteristics – including the target species, the method of engineering, the engineered features, and the planned purpose or use – and may have a unique set of relevant hazards and risks. Because of the diversity of potential applications of gene drive technology, both the Convention on Biological Diversity and the World Health Organization have recommended that risk assessments be conducted on a case-by-case basis.
For more information:
https://genedrivenetwork.org/videos#mxYouTubeR88da54c719d7acb5beb6a53f64c5214b-1
https://www.who.int/publications/i/item/9789240025233
https://bch.cbd.int/protocol/risk_assessment/cp-ra-ahteg-2020-01-04-en-2.pdf
0
0
Leave a Reply
You must be logged in to post a comment.